A 1-Pot Synthesis of the SARS-CoV-2 M ^pro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid

Abstract

A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 64%.